Zobrazeno 1 - 10
of 38
pro vyhledávání: '"CT-P59"'
Autor:
Ji Yeon Lee, Seon Hee Bu, EunHyang Song, Seongcheol Cho, Sungbong Yu, Jungok Kim, Sungmin Kym, Kwang Won Seo, Ki Tae Kwon, Jin Yong Kim, Sunghyun Kim, Keumyoung Ahn, Nahyun Jung, Yeonmi Lee, Yoobin Jung, Chankyoung Hwang, Sang Won Park
Publikováno v:
Infectious Diseases and Therapy, Vol 12, Iss 10, Pp 2417-2435 (2023)
Abstract Introduction Regdanvimab, a neutralising monoclonal antibody (mAb) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), received approval for the treatment of coronavirus disease 2019 (COVID-19) in South Korea in 2021. The M
Externí odkaz:
https://doaj.org/article/2cfbe7051ee749f38846304a4ed3b6f1
Publikováno v:
International Journal of Infectious Diseases, Vol 130, Iss , Pp 94-100 (2023)
Objectives: To evaluate the efficacy and safety of regdanvimab, a neutralizing antibody, in patients with mild-to-moderate SARS-CoV-2 including against the Delta variant. Methods: A single-center, retrospective, observational cohort study in adults w
Externí odkaz:
https://doaj.org/article/1d71c40b49984eaea6e2579ec76be0c6
Publikováno v:
Current Therapeutic Research, Vol 96, Iss , Pp 100675- (2022)
ABSTRACT: Background: In a Phase III study, regdanvimab (CT-P59) reduced the risk of hospitalization or death versus placebo in patients with mild-to-moderate coronavirus disease 2019 (COVID-19). Purpose: We performed a retrospective cohort study of
Externí odkaz:
https://doaj.org/article/6a046dd4333143e1b3fa0a2ebe91b0de
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Hanmi Noh, Jong-In Kim, Ji-Min Seo, Manki Song, Minho Lee, Sang-Seok Oh, Hyo-Young Chung, Sun-Je Woo, Carel A. van Baalen, Eunji Yang, Soo Young Lee, Dong Kyun Ryu, Patricia M. Nuijten, Ki-Sung Kwon, Su-Kyeong Eo, Bobin Kang, Minsoo Kim, Gippeum Lim, Seong-Gyu Kim, Jung-ah Choi, Aloys Sl. Tijsma, Cheol-Min Kim
Publikováno v:
Biochemical and Biophysical Research Communications
The SARS-CoV-2 variant is rapidly spreading across the world and causes to resurge infections. We previously reported that CT-P59 presented its in vivo potency against Beta variants, despite its reduced activity in cell experiments. Yet, it remains u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8945a7c6c7cd1874f874091332241ce9
https://doi.org/10.1016/j.bbrc.2021.09.023
https://doi.org/10.1016/j.bbrc.2021.09.023
Autor:
Jin Gyu Jung, Sunghyun Kim, Bum Soo Kim, Anca Streinu-Cercel, Oana Săndulescu, Da Bee Jeon, Adrian Streinu-Cercel, Seul Gi Lee, Sang Joon Lee, Yeon Sook Kim, Yeo Jin Lee, Jin Yong Kim, Yeon Mi Lee, Min Kyung Kim, Jae-Hyeong Park, Jang Hee Hong, Jeong Eun Park, Young Rock Jang, Na Hyun Jung
Publikováno v:
Clinical Therapeutics
PURPOSE: Neutralizing antibodies can reduce SARS-CoV-2 cellular entry, viral titers, and pathologic damage. CT-P59 (regdanvimab), a SARS-CoV-2 neutralizing monoclonal antibody, was examined in 2 randomized, double-blind, placebo-controlled, single as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be168aec276ef873b11c98eb98586b40
https://doi.org/10.1016/j.clinthera.2021.08.009
https://doi.org/10.1016/j.clinthera.2021.08.009
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Shinwon, Lee, Soon Ok, Lee, Jeong Eun, Lee, Kye-Hyung, Kim, Sun Hee, Lee, Soyoon, Hwang, Shin-Woo, Kim, Hyun-Ha, Chang, Yoonjung, Kim, Sohyun, Bae, A-Sol, Kim, Ki Tae, Kwon
Publikováno v:
International Immunopharmacology
Background Regdanvimab (CT-P59) is a neutralizing antibody authorized in Republic of Korea for the treatment of adult patients with moderate or mild-COVID-19 who are not on supplemental oxygen and have high risk of progressing to severe disease (age
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e23ac117cd61c05ca4c112df62f1d009
http://europepmc.org/articles/PMC8813598
http://europepmc.org/articles/PMC8813598
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Tandile Hermanus, Ki-Sung Kwon, rina song, Minsoo Kim, Prudence Kgagudi, Jong-In Kim, Carel A. van Baalen, Young-Il Kim, Cheol-Min Kim, Patricia M. Nuijten, Young Ki Choi, Penny L. Moore, Dong Kyun Ryu, Aloys Sl. Tijsma, Soo Young Lee, Thandeka Moyo-Gwete
Publikováno v:
Biochemical and Biophysical Research Communications
The global circulation of newly emerging variants of SARS-CoV-2 is a new threat to public health due to their increased transmissibility and immune evasion. Moreover, currently available vaccines and therapeutic antibodies were shown to be less effec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::760fdc72211cdd4621b8f53c21ea1de6
https://doi.org/10.1101/2021.04.27.441707
https://doi.org/10.1101/2021.04.27.441707
